TG Therapeutics (TGTX) is down about 3.5% in Wednesday trading as investors trim exposure ahead of its next quarterly earnings report, which is widely expected before the market opens on Monday, May 4, 2026. With no major same-day company headline surfacing, the move looks driven by positioning and profit-taking after a volatile April stretch heading into the earnings catalyst.

TGTX recently benefited from a catalyst in mid-April when the company said it completed enrollment in its Phase 3 study evaluating a subcutaneous formulation of BRIUMVI for relapsing forms of multiple sclerosis—news that helped lift the shares. After that rally, today’s decline fits a familiar pattern for single-product biotech stories: some investors lock in gains and reduce risk into an earnings event that can reset near-term expectations.

The next key driver is management’s update on BRIUMVI demand trends and 2026 revenue trajectory when Q1 results are released. Traders will also be watching for any commentary on development milestones for the subcutaneous program and timing for future readouts, since incremental clarity on formulation progress can affect perceptions of long-term growth beyond the current IV regimen.